241 related articles for article (PubMed ID: 30496374)
1. A Carboxy-Terminal Monoleucine-Based Motif Participates in the Basolateral Targeting of the Na+/I- Symporter.
Martín M; Modenutti CP; Peyret V; Geysels RC; Darrouzet E; Pourcher T; Masini-Repiso AM; Martí MA; Carrasco N; Nicola JP
Endocrinology; 2019 Jan; 160(1):156-168. PubMed ID: 30496374
[TBL] [Abstract][Full Text] [Related]
2. The PDZ protein SCRIB regulates sodium/iodide symporter (NIS) expression at the basolateral plasma membrane.
Martín M; Salleron L; Peyret V; Geysels RC; Darrouzet E; Lindenthal S; Bernal Barquero CE; Masini-Repiso AM; Pourcher T; Nicola JP
FASEB J; 2021 Aug; 35(8):e21681. PubMed ID: 34196428
[TBL] [Abstract][Full Text] [Related]
3. Implications of Na
Martín M; Geysels RC; Peyret V; Bernal Barquero CE; Masini-Repiso AM; Nicola JP
J Endocr Soc; 2019 Jan; 3(1):222-234. PubMed ID: 30620007
[TBL] [Abstract][Full Text] [Related]
4. The iodide-transport-defect-causing mutation R124H: a δ-amino group at position 124 is critical for maturation and trafficking of the Na+/I- symporter.
Paroder V; Nicola JP; Ginter CS; Carrasco N
J Cell Sci; 2013 Aug; 126(Pt 15):3305-13. PubMed ID: 23690546
[TBL] [Abstract][Full Text] [Related]
5. Basolateral Sorting of the Sodium/Iodide Symporter Is Mediated by Adaptor Protein 1 Clathrin Adaptor Complexes.
Koumarianou P; Fernández-Méndez C; Fajardo-Delgado D; Mielu LM; Santisteban P; De la Vieja A
Thyroid; 2022 Oct; 32(10):1259-1270. PubMed ID: 35833460
[No Abstract] [Full Text] [Related]
6. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism.
Filetti S; Bidart JM; Arturi F; Caillou B; Russo D; Schlumberger M
Eur J Endocrinol; 1999 Nov; 141(5):443-57. PubMed ID: 10576759
[TBL] [Abstract][Full Text] [Related]
7. Immunoanalysis indicates that the sodium iodide symporter is not overexpressed in intracellular compartments in thyroid and breast cancers.
Peyrottes I; Navarro V; Ondo-Mendez A; Marcellin D; Bellanger L; Marsault R; Lindenthal S; Ettore F; Darcourt J; Pourcher T
Eur J Endocrinol; 2009 Feb; 160(2):215-25. PubMed ID: 19029227
[TBL] [Abstract][Full Text] [Related]
8. The Iodide Transport Defect-Causing Y348D Mutation in the Na
Reyna-Neyra A; Jung L; Chakrabarti M; Suárez MX; Amzel LM; Carrasco N
Thyroid; 2021 Aug; 31(8):1272-1281. PubMed ID: 33779310
[No Abstract] [Full Text] [Related]
9. A systematic evaluation of sorting motifs in the sodium-iodide symporter (NIS).
Darrouzet E; Graslin F; Marcellin D; Tcheremisinova I; Marchetti C; Salleron L; Pognonec P; Pourcher T
Biochem J; 2016 Apr; 473(7):919-28. PubMed ID: 26831514
[TBL] [Abstract][Full Text] [Related]
10. Hydrocortisone and purinergic signaling stimulate sodium/iodide symporter (NIS)-mediated iodide transport in breast cancer cells.
Dohán O; De la Vieja A; Carrasco N
Mol Endocrinol; 2006 May; 20(5):1121-37. PubMed ID: 16439463
[TBL] [Abstract][Full Text] [Related]
11. The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance.
Dohán O; De la Vieja A; Paroder V; Riedel C; Artani M; Reed M; Ginter CS; Carrasco N
Endocr Rev; 2003 Feb; 24(1):48-77. PubMed ID: 12588808
[TBL] [Abstract][Full Text] [Related]
12. The Q267E mutation in the sodium/iodide symporter (NIS) causes congenital iodide transport defect (ITD) by decreasing the NIS turnover number.
De La Vieja A; Ginter CS; Carrasco N
J Cell Sci; 2004 Feb; 117(Pt 5):677-87. PubMed ID: 14734652
[TBL] [Abstract][Full Text] [Related]
13. The Sodium/Iodide Symporter (NIS): Molecular Physiology and Preclinical and Clinical Applications.
Ravera S; Reyna-Neyra A; Ferrandino G; Amzel LM; Carrasco N
Annu Rev Physiol; 2017 Feb; 79():261-289. PubMed ID: 28192058
[TBL] [Abstract][Full Text] [Related]
14. Association of low sodium-iodide symporter messenger ribonucleic acid expression in malignant thyroid nodules with increased intracellular protein staining.
Sodré AK; Rubio IG; Galrão AL; Knobel M; Tomimori EK; Alves VA; Kanamura CT; Buchpiguel CA; Watanabe T; Friguglietti CU; Kulcsar MA; Medeiros-Neto G; Camargo RY
J Clin Endocrinol Metab; 2008 Oct; 93(10):4141-5. PubMed ID: 18628528
[TBL] [Abstract][Full Text] [Related]
15. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells.
Schmutzler C; Winzer R; Meissner-Weigl J; Köhrle J
Biochem Biophys Res Commun; 1997 Nov; 240(3):832-8. PubMed ID: 9398654
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of sodium/iodide symporter expression in thyroid and breast cancer.
Kogai T; Taki K; Brent GA
Endocr Relat Cancer; 2006 Sep; 13(3):797-826. PubMed ID: 16954431
[TBL] [Abstract][Full Text] [Related]
17. Na(+)/I(-) symporter activity requires a small and uncharged amino acid residue at position 395.
Dohán O; Gavrielides MV; Ginter C; Amzel LM; Carrasco N
Mol Endocrinol; 2002 Aug; 16(8):1893-902. PubMed ID: 12145342
[TBL] [Abstract][Full Text] [Related]
18. Asn441 plays a key role in folding and function of the Na+/I- symporter (NIS).
Li W; Nicola JP; Amzel LM; Carrasco N
FASEB J; 2013 Aug; 27(8):3229-38. PubMed ID: 23650190
[TBL] [Abstract][Full Text] [Related]
19. Molecular analysis of a congenital iodide transport defect: G543E impairs maturation and trafficking of the Na+/I- symporter.
De la Vieja A; Ginter CS; Carrasco N
Mol Endocrinol; 2005 Nov; 19(11):2847-58. PubMed ID: 15976004
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of regulating NIS transport to the cell membrane and redifferentiation therapy in thyroid cancer.
Cai X; Wang R; Tan J; Meng Z; Li N
Clin Transl Oncol; 2021 Dec; 23(12):2403-2414. PubMed ID: 34100218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
